Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy.
In a study published in Cell Chemical Biology, a research team led by Prof. Tan Weihong and Prof. Wu Qin from the Hangzhou Institute of Medical of the Chinese Academy of Sciences has identified ...
Relacorilant combined with nab-paclitaxel improved progression-free and overall survival in platinum-resistant ovarian cancer patients. The phase 3 ROSELLA trial showed a 30% reduction in recurrence ...
CHICAGO -- Combining investigational relacorilant with nab-paclitaxel (Abraxane) improved progression-free survival (PFS), and demonstrated a clinically meaningful trend towards an overall survival ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...
Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding response rates below 20% and median progression-free survival barely reaching ...
Pembrolizumab combined with weekly paclitaxel ± bevacizumab reduced death risk by 18% and improved median OS by 3.7 months versus paclitaxel ± bevacizumab in all comers. Progression-free survival ...
In a study published in Cell Chemical Biology, a research team led by Prof. TAN Weihong and Prof. WU Qin from the Hangzhou Institute of Medicine of the Chinese Academy of Sciences has identified ...
Relacorilant, a selective glucocorticoid receptor antagonist, combined with nab-paclitaxel significantly improved progression-free survival in women with platinum-resistant ovarian cancer. The interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results